Search company, investor...

Predict your next investment

Corporation
kyowakirin.co.jp

Investments

4

Portfolio Exits

2

Partners & Customers

10

About Kyowa Kirin

Kyowa Kirin is a global specialty pharmaceutical company based in Japan. They focus on the anti-body technologies in the core therapeutic areas of oncology, nephrology, and immunology.

Headquarters Location

9-2 Otemachi Chiyoda Ward Otemachi Financial City Grand Cube

Tokyo, 100-0004,

Japan

03-5205-7200

Want to inform investors similar to Kyowa Kirin about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Kyowa Kirin News

11:00 ET Kyowa Kirin Continues Commitment to Making Dreams Possible

May 30, 2023

News provided by Share this article Share this article Global specialty pharmaceutical company supports Dream Foundation's work to provide comfort, closure, and inspiration at the end of life. BEDMINSTER, N.J. and SANTA BARBARA, Calif., May 30, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin. Ltd., a global specialty pharmaceutical company, has extended its support of Dream Foundation - the only national dream-granting organization for terminally ill adults, fulfilling more than 34,000 final Dreams across the United States and Puerto Rico. The renewed commitment marks the seventh year of Kyowa Kirin and Dream Foundation working together to make final Dreams come true and will extend through 2024. Since their initial partnership in 2017, Kyowa Kirin and Dream Foundation have brought 100 final Dreams to life. These Dreams have been fulfilled in a range of ways, including family vacations to Disneyland® - helping families make final memories to be cherished, to meetings with personal heroes - bringing a sense of completeness and joy, and the provision of tablets and laptops - to reunite loved ones. In addition to making final Dreams come true, the partnership has allowed U.S.-based Kyowa Kirin employees to be directly involved in Dream deliveries, where they meet Dream recipients and their families and celebrate their lives and final Dreams. This dedication aligns with Dream Foundation's mission to fulfill the final Dreams of terminally ill adults and their families, a critical part of end-of-life care. "Kyowa Kirin's continued commitment to our mission is miraculous," says Dream Foundation's Chief Executive Officer, Kisa Heyer. "Year after year, Kyowa Kirin and its employees have shown a dedication and passion for our Dream recipients, delivering Dreams that directly impact and improve the lives of the recipient and their families." Sandy Vaziri, one of Kyowa Kirin's Regional Sales Managers, appears in " Language of Dreams ," a 2020 film by award-winning director Peter Sasowsky, produced by Dream Foundation. The film is a celebration of life itself, what it means to be human and the redeeming power of supporting each other through difficult times. "At Kyowa Kirin, we strive to have a profound impact on patients' lives. That purpose starts with the novel therapies we discover and deliver and extends into the communities we are a part of," says Lauren Walrath, VP, Public Affairs, North America. "Medical advances can help many patients live with and manage disease. But for those who face a terminal diagnosis, we are glad to offer a final chance to spend time with their loved ones, doing something very special. We believe those moments matter a great deal." Dream Recipients must be at least 18 years old, have a life expectancy of twelve months or less, and lack the resources to achieve their Dreams on their own. To apply for a Dream, please visit dreamfoundation.org/how-to-apply . About Dream Foundation: Dream Foundation, the only national dream-granting organization for terminally ill adults, fulfills final Dreams that provide inspiration, comfort and closure at the end of life. With the support of a nationwide network of volunteers, hospices, health care organizations and committed donors, Dream Foundation has served more than 34,000 final Dreams since its inception in 1994. Dream Foundation receives no state or federal funding—we rely solely on private donations. To support our mission please visit DreamFoundation.org/donate . About Kyowa Kirin Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based global specialty pharmaceutical company with a more than 70-year heritage, the company applies cutting-edge science, including expertise in antibody research and engineering, to address the needs of patients across multiple therapeutic areas such as nephrology, oncology, immunology/allergy, and neurology. Across its four regions – Japan, Asia Pacific, North America and EMEA/International – Kyowa Kirin focuses on its purpose, to make people smile, and is united by its shared values of commitment to life, teamwork, innovation, and integrity. Learn more about Kyowa Kirin North America at https://kkna.kyowakirin.com/ . SOURCE Dream Foundation

Kyowa Kirin Investments

4 Investments

Kyowa Kirin has made 4 investments. Their latest investment was in Ring Therapeutics as part of their Series C on March 3, 2023.

CBI Logo

Kyowa Kirin Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/9/2023

Series C

Ring Therapeutics

$86.5M

Yes

2

11/26/2019

Corporate Minority - P2P

Subscribe to see more

$99M

Subscribe to see more

10

1/11/2010

Partnership

Subscribe to see more

$99M

Subscribe to see more

0

9/23/2007

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/9/2023

11/26/2019

1/11/2010

9/23/2007

Round

Series C

Corporate Minority - P2P

Partnership

Series A - II

Company

Ring Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$86.5M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

0

10

Kyowa Kirin Portfolio Exits

2 Portfolio Exits

Kyowa Kirin has 2 portfolio exits. Their latest portfolio exit was Solasia Pharma on March 23, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/23/2017

IPO

$99M

Public

1

1/30/2014

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/23/2017

1/30/2014

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

1

10

Kyowa Kirin Acquisitions

1 Acquisition

Kyowa Kirin acquired 1 company. Their latest acquisition was Archimedes Pharma on July 11, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/11/2014

$99M

Acquired

1

Date

7/11/2014

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

1

Kyowa Kirin Partners & Customers

10 Partners and customers

Kyowa Kirin has 10 strategic partners and customers. Kyowa Kirin recently partnered with MEI Pharma on July 7, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

7/18/2022

Licensor

United States

MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy

In April 2020 , MEI Pharma , Inc. and Kyowa Kirin entered a global license , development , and commercialization agreement to further develop and commercialize zandelisib .

2

6/30/2022

Licensor

Switzerland

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

AMSTERDAM , June 30 , 2022 / PRNewswire / -- Synaffix , a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates -LRB- ADC Therapeutics 's -RRB- with best-in-class therapeutic index , today announces that Kyowa Kirin -LRB- Kyowa Kirin , TSE : 4151 -RRB- , a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies , has expanded the license agreement with Synaffix -LRB- announced in August 2021 -RRB- by adding a third ADC Therapeutics target to its research evaluation and development efforts under this deal .

1

6/30/2022

Licensor

Netherlands

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data – Synaffix

AMSTERDAM , NETHERLANDS -- June 30 , 2022 -- Synaffix , a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates -LRB- ADC 's -RRB- with best-in-class therapeutic index , today announces that Kyowa Kirin -LRB- Kyowa Kirin , TSE : 4151 -RRB- , a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies , has expanded the license agreement with Synaffix -LRB- announced in August 2021 -RRB- by adding a third ADC target to its research evaluation and development efforts under this deal .

1

6/4/2022

Licensor

United States

Subscribe to see more

Subscribe to see more

10

5/18/2022

Partner

Japan

Subscribe to see more

Subscribe to see more

10

Date

7/18/2022

6/30/2022

6/30/2022

6/4/2022

5/18/2022

Type

Licensor

Licensor

Licensor

Licensor

Partner

Business Partner

Country

United States

Switzerland

Netherlands

United States

Japan

News Snippet

MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy

In April 2020 , MEI Pharma , Inc. and Kyowa Kirin entered a global license , development , and commercialization agreement to further develop and commercialize zandelisib .

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

AMSTERDAM , June 30 , 2022 / PRNewswire / -- Synaffix , a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates -LRB- ADC Therapeutics 's -RRB- with best-in-class therapeutic index , today announces that Kyowa Kirin -LRB- Kyowa Kirin , TSE : 4151 -RRB- , a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies , has expanded the license agreement with Synaffix -LRB- announced in August 2021 -RRB- by adding a third ADC Therapeutics target to its research evaluation and development efforts under this deal .

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data – Synaffix

AMSTERDAM , NETHERLANDS -- June 30 , 2022 -- Synaffix , a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates -LRB- ADC 's -RRB- with best-in-class therapeutic index , today announces that Kyowa Kirin -LRB- Kyowa Kirin , TSE : 4151 -RRB- , a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies , has expanded the license agreement with Synaffix -LRB- announced in August 2021 -RRB- by adding a third ADC target to its research evaluation and development efforts under this deal .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.